نتایج جستجو برای: pediatric aml and prognosis

تعداد نتایج: 16873517  

2014
Carolyn S. Grove George S. Vassiliou

Acute myeloid leukaemia (AML) is an uncontrolled clonal proliferation of abnormal myeloid progenitor cells in the bone marrow and blood. Advances in cancer genomics have revealed the spectrum of somatic mutations that give rise to human AML and drawn our attention to its molecular evolution and clonal architecture. It is now evident that most AML genomes harbour small numbers of mutations, whic...

Journal: :Haematologica 2008
Meletios Athanasios Dimopoulos Efstathios Kastritis Sossana Delimpassi Athanasios Zomas Marie Christine Kyrtsonis Konstantinos Zervas

| 1420 | haematologica | 2008; 93(9) not need an alloSCT for cure after relapse. Results of the ongoing International BFM Study Group Pediatric Relapsed AML protocol, will contribute to this discussion in the near future. The Dutch and literature data suggest that randomized studies of the role of alloSCT in subgroups of relapsed AML are required. Meanwhile, experimental allogeneic SCT procedur...

2016
Aleksandra Butrym Justyna Rybka Dagmara Baczyńska Rafał Poręba Kazimierz Kuliczkowski Grzegorz Mazur

UNLABELLED Acute myeloid leukemia (AML) is a heterogeneous disease with different clinical course and prognosis. microRNA-29 (miR-29) family of non-coding small RNAs can play an important role in pathogenesis of AML, but also can influence response to therapy.The purpose of the study was to evaluate miR-29c expression in AML patients in relationship to clinical parameters and response to chemot...

2008
Emily Mathews Timothy Laurie Kenneth O'Riordan Chadi Nabhan

Liver involvement with acute myeloid leukemia (AML) is rarely reported. The majority of published cases suggest a cholestatic picture and obstructive jaundice at presentation. On the contrary, our patient presented with transaminitis without cholestasis. Elevated liver function tests persisted in our patient despite cholecystectomy; however, they normalized with chemotherapy administration, sug...

2017

Acute Myelocytic Leukemia (AML) Profile, Chromosome Analysis With Reflex to FLT3, CEBPA, and NPM1 . . . . . 511972 CPT Contact CPT coding department at 800-222-7566, ext. 6-8400. Synonyms AML Use Diagnostic and prognostic test for acute myeloid leukemia Limitations Molecular mutations not targeted by the probes included in this profile will not be detected. This test was developed and its perfo...

Journal: :Blood 2012
Hsin-An Hou Yuan-Yeh Kuo Chieh-Yu Liu Wen-Chien Chou Ming Cheng Lee Chien-Yuan Chen Liang-In Lin Mei-Hsuan Tseng Chi-Fei Huang Ying-Chieh Chiang Fen-Yu Lee Ming-Chih Liu Chia-Wen Liu Jih-Luh Tang Ming Yao Shang-Yi Huang Bor-Sheng Ko Szu-Chun Hsu Shang-Ju Wu Woei Tsay Yao-Chang Chen Hwei-Fang Tien

DNMT3A mutations are associated with poor prognosis in acute myeloid leukemia (AML), but the stability of this mutation during the clinical course remains unclear. In the present study of 500 patients with de novo AML, DNMT3A mutations were identified in 14% of total patients and in 22.9% of AML patients with normal karyotype. DNMT3A mutations were positively associated with older age, higher W...

2013
Audrey Astori Hanne Fredly Thomas Aquinas Aloysius Lars Bullinger Véronique Mansat-De Mas Pierre de la Grange François Delhommeau Karen Marie Hagen Christian Récher Isabelle Dusanter-Fourt Stian Knappskog Johan Richard Lillehaug Frédéric Pendino Øystein Bruserudg

The retinoid-responsive gene CXXC5 localizes to the 5q31.2 chromosomal region and encodes a retinoid-inducible nuclear factor (RINF) that seems important during normal myelopoiesis. We investigated CXXC5/RINF expression in primary human acute myeloid leukemia (AML) cells derived from 594 patients, and a wide variation in CXXC5/RINF mRNA levels was observed both in the immature leukemic myelobla...

Journal: :Seminars in hematology 2014
Timothy Graubert Richard Stone

Acute myeloid leukemia (AML) is a heterogeneous disease, characterized by frequent resistance to available chemotherapeutic agents. The basic therapy for patients with AML has changed little over the past 30 years. Improvements in outcome in recent decades in younger adult cohorts have generally been ascribed to better supportive care (ie, transfusion and antimicrobial therapy); older adults wi...

2017
Amr Rafat Elhamamsy Muhammad Suleiman El Sharkawy Ahmed Farouk Zanaty Mohammed Ahmed Mahrous Ahmed Ezzat Mohamed Eslam Ahmed Abushaaban

MicroRNAs (miRNAs) are small non-coding RNAs that function as post-transcriptional gene expression regulators. The expression profiling of miRNAs has already entered into cancer clinics as diagnostic and prognostic biomarkers to assess tumor initiation, progression and response to treatment in cancer patients. Recent studies have opened the way for the use of circulating miRNAs as non-invasive ...

2017
Victor Pallarès Montserrat Hoyos M. Carmen Chillón Eva Barragán M. Isabel Prieto Conde Marta Llop María Virtudes Céspedes Josep F. Nomdedeu Salut Brunet Miguel Ángel Sanz Marcos González-Díaz Jorge Sierra Isolda Casanova Ramon Mangues

Intermediate-risk acute myeloid leukemia (IR-AML) is the largest subgroup of AML patients and is highly heterogeneous. Whereas adverse and favourable risk patients have well-established treatment protocols, IR-AML patients have not. It is, therefore, crucial to find novel factors that stratify this subgroup to implement risk-adapted strategies. The CAS (Crk-associated substrate) adaptor protein...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید